All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

ASH 2020: Highlights for patients with TP53-mutated AML

Jan 20, 2021
Share:

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE, about the highlights for patients with TP53-mutated AML from ASH 2020.

ASH 2020: Highlights for patients with TP53-mutated AML

Platzbecker highlights the findings from a study evaluating the combination of azacitidine and magrolimab in patients with AML, including TP53-mutant AML.

Share: